Open AccessSwitching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances
Author(s) -
Giuseppe Lapadula,
Davide Paolo Bernasconi,
Francesca Bai,
Emanuele Focà,
Antonio Di Biagio,
Stefano Bonora,
Francesco Castelli,
Nicola Squillace,
Alessandra Bandera,
Antonella d’Arminio Monforte,
Guglielmo Marco Migliorino,
Andrea Gori
Publication year - 2020
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002377
Subject(s) - neurocognitive , rilpivirine , efavirenz , medicine , anxiety , randomized controlled trial , emtricitabine , pittsburgh sleep quality index , adverse effect , cognition , psychiatry , human immunodeficiency virus (hiv) , sleep quality , viral load , family medicine , antiretroviral therapy
Efavirenz (EFV) association with neurocognitive impairment is debated. Whether switching away from EFV improves neurocognitive performances is still controversial.